Inlecitug is a chimeric monoclonal antibody that targets the human KDR (kinase insert domain receptor). By specifically binding to KDR, Inlecitug blocks the interaction between vascular endothelial growth factor (VEGF) and KDR, thereby inhibiting angiogenesis and exerting antitumor activity. Inlecitug holds potential for cancer research.